Miri Ben-Ami
President chez Immune Pharmaceuticals Ltd.
Profil
Miri Ben-Ami is a professional with experience in various firms.
Currently, she holds two positions as a Member of the Governing Board at The Association of Publicly Traded Cos.
(Israel) and as the President of Immune Pharmaceuticals Ltd.
In the past, she worked as the Chief Executive Officer at Aposense Ltd., a Member of the Global Research & Development Team at Teva Pharmaceutical Industries Ltd., and as the Executive Vice President-Oncology at Immune Pharmaceuticals, Inc. She pursued her undergraduate and doctorate degrees from the University of the Witwatersrand.
Postes actifs de Miri Ben-Ami
| Sociétés | Poste | Début |
|---|---|---|
Immune Pharmaceuticals Ltd.
 Immune Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Immune Pharmaceuticals, Inc., Immune Pharmaceuticals Ltd. develops pharmaceutical products for the treatment of cancer and pain. The company is based in Herzliya-Pituach, Israel. Immune Pharmaceuticals was acquired by EpiCept Corp. on August 26, 2013 for $21.43 million. | President | - |
| The Association of Publicly Traded Cos. (Israel) | Corporate Officer/Principal | - |
Anciens postes connus de Miri Ben-Ami
| Sociétés | Poste | Fin |
|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 18/08/2011 |
| IMMUNE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| APOSENSE LTD | Directeur Général | - |
Formation de Miri Ben-Ami
| University of the Witwatersrand | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| Entreprise privées | 4 |
|---|---|
Aposense Ltd.
 Aposense Ltd. Pharmaceuticals: MajorHealth Technology Aposense Ltd. engages in the provision of proprietary conjugates. It offers platform technology which comprises the rational design of small molecular moieties with the increased affinity to the cell membranes imparting the conjugates compound with improved drug properties such as extended life span oral bioavailabity and selective at target site. The company was founded by Ilan Ziv and Jacob Gottenstein on October 9, 1996 and is headquartered in Petach-Tikva, Israel. | Health Technology |
| The Association of Publicly Traded Cos. (Israel) | |
Immune Pharmaceuticals Ltd.
Immune Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Immune Pharmaceuticals, Inc., Immune Pharmaceuticals Ltd. develops pharmaceutical products for the treatment of cancer and pain. The company is based in Herzliya-Pituach, Israel. Immune Pharmaceuticals was acquired by EpiCept Corp. on August 26, 2013 for $21.43 million. | Health Technology |
Immune Pharmaceuticals, Inc.
 Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |